Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for clarifying!
Thanks for the info Tbear
Went up that amount or went to that amount?
Would’ve been nice to have pushed through the .40 barrier. Next week!!
Agree 100% with you Penny.
This is fabulous news!
Good morning!
What’s up? Down in premarket.
Definite positive!
Who bought/sold 1.2mm shares?
Correction on forgiveness. You don’t get to apply when you feel like it if you don’t want to pay interest on the outstanding monies prior to your forgiveness. Forgiveness had to have been applied for as interest started as of September 1.
News…. Sep. 27, 2021 8:12 AM ETNRx Pharmaceuticals, Inc. (NRXP)Relief Therapeutics Holding AG (RLFTF)By: Mamta Mayani, SA News Editor1 Comment
Variant mutation Covid-19 coronavirus. Showing genetic mutation
Bill Oxford/iStock via Getty Images
NRx Pharmaceuticals (NASDAQ:NRXP) perks up 3% premarket after announcing top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with Zyesami (aviptadil).
A statistically significant difference in both survival and recovery from respiratory failure was reported at 28 days.
Top-line results show a statistically significant (P<.0001) 3-fold advantage in likelihood of being alive at one year post treatment (60% vs. 20%) among those treated with Zyesami, in addition to standard of care, compared to those who received the standard of care alone.
These findings are soon to be published in a peer-reviewed journal.
Zyesami remains under FDA review for emergency use authorization in patients suffering critical COVID-19 with respiratory failure.
Zyesami (aviptadil) is being developed in partnership with Relief Therapeutics (OTCQB:RLFTF).
Last month, NRXP reported positive Zyesami results in patients with respiratory distress due to COVID-19.
Now Read: IQVIA partners with NRX Pharma to support regulatory pathway for COVID-19 therapy
1 Comment
Share
Comment
Get alerts on
NRXP - NRx Pharmaceuticals, Inc.
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
Source: InvestorsHub NewsWire
TORONTO, Sept. 21, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares® Investments LLC ("AdvisorShares"), a leading sponsor of actively managed exchange-traded funds (ETFs) has included Revive Therapeutics in the inaugural launch of its AdvisorShares Psychedelics ETF ("PSIL").
PSIL invests in the emerging psychedelic drugs sector, offering exposure to biotechnology, pharmaceutical, and life sciences companies leading the way in this nascent industry. The ETF at launch includes 16 publicly listed companies offering investors exposure to companies who are leading the way in the emerging psychedelics space.
"We are pleased to be included in the inaugural launch of the PSIL ETF as it provides further validation of our pharmaceutical psychedelics strategy in pursuing novel uses, formulations and delivery forms of psilocybin for the treatment of mental health and neurological conditions," said Michael Frank, CEO of the Company.
PSIL commenced trading on September 16, 2021, debuting on the New York Stock Exchange under ticker symbol (NYSE: PSIL). The holdings of PSIL and its current portfolio weights are regularly updated and available at https://advisorshares.com/etfs/psil/.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Come on! WTF
Awesome…thank you Blue! I haven’t posted much over last several months but I’m very long in RVVTF. Hope to hear good news soon.
Gig ‘Em horns!! God Bless Texas
That is an outstanding reply CW. Thank you for submitting it.
Someone reach out to Tucker. Make him aware if he’s not already. He would probably appreciate our frustrations.
Yes great read!
Thank you Lakota for your post. I’m all in and looking forward to strong year end finish with a solid springboard in to 2022. The best to all of us longs!
Trades pushing through on “the ask”!
What are people’s thoughts on what “certain indications” means. It is ckear lawyer language that imho insinuates personal perspective of each entity, therefore being misunderstood by either entity this causing dispute. The word certain is a subjective term. This statement should be clarified IMO.
Turbo…what are your thoughts?
what does “based on certain indications” imply?
we and Relief Therapeutics have agreed to share profits from ZYESAMI for certain indications, based on Relief Therapeutics’ funding of our development efforts. ”
Thank you for a simple and clear way of providing needed perspective. I too have been suspect and have felt there to maybe be an undertone of holding back solid therapeutics so as to allow govt to continue its overreach under the guise of saving lives via forced vaccinations. Personally I think there still may be the intention however your perspective on the realities of fda approval process and the necessary steps and timelines is very much appreciated and highly noted.
Thanks Rio!
3BB
“The decline in Pro-C3 that was observed in the AMBITION trial puts us well within the range of NASH data published by other companies with later-stage NASH drug candidates,” said Hepion’s Chief Medical Officer, Todd Hobbs MD.
“But notably, these declines in Pro-C3 with CRV431 occurred in only 4 weeks, compared to declines with other agents, where the changes occurred over several months.”
What is the significance of only 4 weeks?Sentence has a negative undertone.
Agree wholeheartedly with you.
Worthwhile read if you haven’t already.
Ken Tapp
Chairman & CEO at Social Life Network, Inc. (OTC: WDLF)
Social Life Network, Inc.Harvard Business School
Englewood, Colorado, United States500+ connections
Join to Connect
About
A founder and co-founder of multiple internet technology companies over the past 25 years. Started tech career in 1995 as code developer and database administrator for the real estate tech startups, Realtor.com & HomeBuilder.com ...through the IPO as MOVE, in 1999.
After leaving MOVE.COM at the end of 2000, Ken spent the next 11 years as a venture capitalist, investing in more than 20 internet tech startups. He has held the positions of Chairman, CEO, CFO, CTO, COO, Advisor and Director in multiple real estate tech companies here in the U.S. and internationally from 2000 thru 2012.
In January of 2013, he co-founded an AI and Blockchain-powered social networking and e-commerce platform, that has since launched niche social network marketplaces in residential real estate, multiple sports industries including soccer, tennis, hunting, fishing and camping, as well as the financial markets and the emerging alternative medicine industry.
The ask is moving nicely today.
Whats up…no trades
Lol!!! Funny Playa…
Congrats on a solid dd Gat!
Ditto that!
RADNOR, Pa., Aug. 26, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA). In May, NRx submitted an application for EUA to the FDA for ZYESAMI™ (aviptadil) for patients suffering from Critical COVID-19 with respiratory failure.
What? Why are you posting forklifts?
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research Hospital
Medicinal mushroom compound with anticancer activities that have minimal effects on normal cells
Showed superior potency against aggressive breast cancer with potential to treat aggressive malignancies such as triple negative and inflammatory breast cancers
Advancing IND-enabling studies for FDA clinical trials
Michael Frank, CEO of the Company commented, “We are very excited about the new addition to our clinical-stage product pipeline as part of our long-term strategy of unlocking the therapeutic potential of medicinal mushrooms such as psilocybin and Ganoderma lucidum to treat mental health, substance abuse and aggressive cancers. Our intention is to build off from the research conducted at St. Jude Children’s Research Hospital and UCC by advancing towards FDA IND-enabling studies to allow for human clinical studies.”
Yesterday primarily buying and today primarily selling....hmmmm
More than 630k shares on the bid and only 18,000 shares offered on the ask. Not sure what's up but somethings is happening. Tons of buying.
My most speculative hold right now and it's the one with buying....Crazy stuff.
3bb